United Kingdom Diabetes Drugs Market Size
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 1.06 Billion |
| Market Size (2029) | USD 1.24 Billion |
| CAGR (2024 - 2029) | 3.05 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
United Kingdom Diabetes Drugs Market Analysis
The United Kingdom Diabetes Drugs Market size is estimated at USD 1.06 billion in 2024, and is expected to reach USD 1.24 billion by 2029, growing at a CAGR of 3.05% during the forecast period (2024-2029).
Diabetes prevalence data shows an increase in the number of people living with a diabetes diagnosis in the UK. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of the increasing usage of diabetic drugs.
The World Health Assembly agreed on a Resolution on strengthening the prevention and control of diabetes. It recommends action in areas including increasing access to insulin; promoting convergence and harmonization of regulatory requirements for insulin and other medicines and health products for the treatment of diabetes; and assessing the feasibility and potential value of establishing a web-based tool to share information relevant to the transparency of markets for diabetes medicines and health products.
Anti-diabetic drugs help diabetes patients control their condition and lower the risk of diabetes complications. People with diabetes may need to take anti-diabetic drugs for their whole lives to control their blood glucose levels and avoid hypoglycemia and hyperglycemia. Oral anti-diabetic agents present the advantages of easier management and lower cost. So they became an attractive alternative to insulin with better acceptance, which enhances adherence to the treatment.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
United Kingdom Diabetes Drugs Market Trends
The oral anti-diabetic drugs segment holds the highest market share in the United Kingdom Diabetes Drugs Market in the current year
The oral anti-diabetic drugs segment holds the highest market share of about 64.5% in the United Kingdom Diabetes Drugs Market in the current year.
Oral Anti-Diabetic Drugs are available internationally and are recommended for use when escalation of treatment for type 2 diabetes is required along with lifestyle management. Oral agents are typically the first medications used in treating type 2 diabetes due to their wide range of efficacy, safety, and mechanisms of action.
Any medicinal product commercially available in the United Kingdom is eligible for reimbursement. It means the NHS refunds the costs of the medicine to the dispensing pharmacist or doctor, apart from a few exceptions. Various steps are being taken in the direction of controlling diabetes. An electronic version of a personalized Diabetes United Kingdom Management Plan is available for completion on EMIS Web. The plan can record the objectives and steps agreed upon with the patient and generate an information prescription.
The information prescription can be printed and given to the patient, and an electronic version can be saved in the patient's care record. The Diabetes United Kingdom Management Plan protocols need to be activated and generate a pop-up alert for patients if they are pregnant, suffer from kidney disease, or a raised BP/HbA1c/Cholesterol value, and include no record of a diabetes management plan in the last 6 months. It is also applicable if there is no eGFR or ACR test record in the last 13 months and no record of a Patient Health Questionnaire recorded in the last 3 months.
Owing to the above factors, the market will likely continue to grow.
Glucagon-like Peptide-1 Receptor Agonist Segment is Expected to Dominate the United Kingdom Diabetes Drugs Market in terms of revenue over the forecast period
Glucagon-like Peptide-1 Receptor Agonist Segment is expected to dominate the United Kingdom Diabetes Drugs Market in revenue and register a CAGR of more than 2.5% over the forecast period.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications used for treating type 2 diabetes, and some drugs are also approved for obesity. One of the benefits of this class of drugs over older insulin secretagogues, such as sulfonylureas or meglitinides, is that they include a lower risk of causing hypoglycemia. Besides being important glucose-lowering agents, GLP-1RAs contain significant anti-inflammatory and pulmonary protective effects and benefit gut microbes' composition.
The Association of British HealthTech Industries (ABHI) is a trade association for the medical technology sector in the United Kingdom. The National Service Framework (NSF) program is improving services by setting national standards to drive service quality and tackle variations in care. The Association of British HealthTech Industries launched a diabetes section, enabling diabetes technology companies to work together in the first forum of its kind. The ABHI group is for any health technology company interested in diabetes care.
The disease's growing incidence, prevalence, and progressive nature encouraged the development of new drugs to provide additional treatment options for diabetic patients. The roll-out of many new products, increasing international research collaborations in technology advancement, and increasing awareness about diabetes among the people are some market opportunities for the players in the United Kingdom diabetes drugs market.
United Kingdom Diabetes Drugs Industry Overview
The United Kingdom Diabetes Drugs Market is fragmented, with major manufacturers, namely Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca, holding a presence in the region. A major share of the market is held by manufacturers concomitant with strategy-based M&A operations and constantly entering the market to generate new revenue streams and boost existing ones. These measures taken by the market players will ensure a competitive marketplace, forcing companies to experiment with new technologies.
United Kingdom Diabetes Drugs Market Leaders
-
AstraZeneca
-
Boehringer Ingelheim
-
Novo Nordisk A/S
-
Sanofi Aventis
-
Eli Lilly and Company
*Disclaimer: Major Players sorted in no particular order
United Kingdom Diabetes Drugs Market News
- Septmber 2023: Lilly's diabetes medication Mounjaro has been given the green light by the UK regulatory body. According to the National Institute for Health and Care Excellence (NICE), approximately 180,000 individuals are projected to see positive outcomes from this innovative therapy.
- March 2022: Eli Lilly and Boehringer Ingelheim gained approval for heart failure treatment from the EU for sodium-glucose co-transporter-2-inhibitor (SGLT2-I) and Jardiance (empagliflozin). Previously Jardiance gained a label expansion for treating heart failure in the US.
United Kingdom Diabetes Drugs Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 Insulins
5.1.1 Basal or Long Acting Insulins
5.1.1.1 Lantus (Insulin Glargine)
5.1.1.2 Levemir (Insulin Detemir)
5.1.1.3 Toujeo (Insulin Glargine)
5.1.1.4 Tresiba (Insulin Degludec)
5.1.1.5 Basaglar (Insulin Glargine)
5.1.2 Bolus or Fast Acting Insulins
5.1.2.1 NovoRapid/Novolog (Insulin Aspart)
5.1.2.2 Humalog (Insulin Lispro)
5.1.2.3 Apidra (Insulin Glulisine)
5.1.3 Traditional Human Insulins
5.1.3.1 Novolin/Actrapid/Insulatard
5.1.3.2 Humulin
5.1.3.3 Insuman
5.1.4 Biosimilar Insulins
5.1.4.1 Insulin Glargine Biosimilars
5.1.4.2 Human Insulin Biosimilars
5.2 Oral Anti-diabetic drugs
5.2.1 Biguanides
5.2.1.1 Metformin
5.2.2 Alpha-Glucosidase Inhibitors
5.2.2.1 Alpha-Glucosidase Inhibitors
5.2.3 Dopamine D2 receptor agonist
5.2.3.1 Bromocriptin
5.2.4 SGLT-2 inhibitors
5.2.4.1 Invokana (Canagliflozin)
5.2.4.2 Jardiance (Empagliflozin)
5.2.4.3 Farxiga/Forxiga (Dapagliflozin)
5.2.4.4 Suglat (Ipragliflozin)
5.2.5 DPP-4 inhibitors
5.2.5.1 Onglyza (Saxagliptin)
5.2.5.2 Tradjenta (Linagliptin)
5.2.5.3 Vipidia/Nesina(Alogliptin)
5.2.5.4 Galvus (Vildagliptin)
5.2.6 Sulfonylureas
5.2.6.1 Sulfonylureas
5.2.7 Meglitinides
5.2.7.1 Meglitinides
5.3 Non-Insulin Injectable drugs
5.3.1 GLP-1 receptor agonists
5.3.1.1 Victoza (Liraglutide)
5.3.1.2 Byetta (Exenatide)
5.3.1.3 Bydureon (Exenatide)
5.3.1.4 Trulicity (Dulaglutide)
5.3.1.5 Lyxumia (Lixisenatide)
5.3.2 Amylin Analogue
5.3.2.1 Symlin (Pramlintide)
5.4 Combination drugs
5.4.1 Insulin combinations
5.4.1.1 NovoMix (Biphasic Insulin Aspart)
5.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
5.4.1.3 Xultophy (Insulin Degludec and Liraglutide)
5.4.2 Oral Combinations
5.4.2.1 Janumet (Sitagliptin and Metformin)
6. MARKET INDICATORS
6.1 Type-1 Diabetic Population
6.2 Type-2 Diabetic Population
7. COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk A/S
7.1.2 Takeda
7.1.3 Pfizer
7.1.4 Eli Lilly
7.1.5 Janssen Pharmaceuticals
7.1.6 Astellas
7.1.7 Boehringer Ingelheim
7.1.8 Merck and Co.
7.1.9 AstraZeneca
7.1.10 Bristol Myers Squibb
7.1.11 Novartis
7.1.12 Sanofi Aventis
- *List Not Exhaustive
7.2 COMPANY SHARE ANALYSIS
7.2.1 Novo Nordisk A/S
7.2.2 Sanofi Aventis
7.2.3 Eli Lilly
7.2.4 Merck and Co.
7.2.5 Others
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
United Kingdom Diabetes Drugs Industry Segmentation
Diabetes Drugs are used to manage diabetes mellitus by lowering the glucose level in the blood. The United Kingdom Diabetes Drugs Market is segmented into drugs. The report offers the value (in USD) and volume (in units) for the above segments.
| Insulins | |||||||
| |||||||
| |||||||
| |||||||
|
| Oral Anti-diabetic drugs | ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
|
| Non-Insulin Injectable drugs | |||||||
| |||||||
|
| Combination drugs | |||||
| |||||
|
United Kingdom Diabetes Drugs Market Research FAQs
How big is the United Kingdom Diabetes Drugs Market?
The United Kingdom Diabetes Drugs Market size is expected to reach USD 1.06 billion in 2024 and grow at a CAGR of 3.05% to reach USD 1.24 billion by 2029.
What is the current United Kingdom Diabetes Drugs Market size?
In 2024, the United Kingdom Diabetes Drugs Market size is expected to reach USD 1.06 billion.
Who are the key players in United Kingdom Diabetes Drugs Market?
AstraZeneca, Boehringer Ingelheim, Novo Nordisk A/S, Sanofi Aventis and Eli Lilly and Company are the major companies operating in the United Kingdom Diabetes Drugs Market.
What years does this United Kingdom Diabetes Drugs Market cover, and what was the market size in 2023?
In 2023, the United Kingdom Diabetes Drugs Market size was estimated at USD 1.03 billion. The report covers the United Kingdom Diabetes Drugs Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the United Kingdom Diabetes Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
UK Diabetes Drugs Industry Report
Statistics for the 2024 UK Diabetes Drugs market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. UK Diabetes Drugs analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
